Verona Pharma (VRNA) Stock Forecast & Price Target

Compare

874 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRNA Analyst Ratings

Hold

1 Buy

10 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Verona

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRNA Stock 12 Month Forecast

Average Price Target

$106.22

▲(1.37%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $106.22 with a high forecast of $107.00 and a low forecast of $100.00. The average price target represents a 1.37% change from the last price of $104.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","108":"$108","37.5":"$37.5","84.5":"$84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,37.5,61,84.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.69076923076923,92.90153846153846,94.1123076923077,95.32307692307693,96.53384615384616,97.74461538461539,98.95538461538462,100.16615384615385,101.37692307692308,102.58769230769231,103.79846153846154,105.00923076923077,{"y":106.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.21230769230769,91.94461538461539,92.67692307692307,93.40923076923077,94.14153846153846,94.87384615384616,95.60615384615384,96.33846153846154,97.07076923076923,97.80307692307693,98.53538461538461,99.2676923076923,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$107.00

Average Price Target$106.22

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$90→$107

Hold

2.12%

Upside

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan PachaiyappanRoth MKM

Roth MKM

$116→$107

Hold

2.12%

Upside

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas ShraderBTIG

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon LeeTruist Financial

Truist Financial

$100→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen RahimiPiper Sandler

Piper Sandler

$160→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Mohit BansalWells Fargo

Wells Fargo

$138→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward NashCanaccord Genuity

Canaccord Genuity

$106→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew TsaiJefferies

Jefferies

$140→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara BancroftTD Cowen

TD Cowen

$100→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

-4.56%

Downside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$90→$107

Hold

2.12%

Upside

Downgraded

07/14/25

Verona Pharma downgraded to Neutral from Buy at H.C. WainwrightVerona Pharma downgraded to Neutral from Buy at H.C. Wainwright

Boobalan PachaiyappanRoth MKM

Roth MKM

$116→$107

Hold

2.12%

Upside

Downgraded

07/12/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Verona Pharma (NASDAQ: VRNA)

Thomas ShraderBTIG

BTIG

―

Hold

―

Downgraded

07/11/25

Verona Pharma downgraded to Neutral from Buy at BTIGVerona Pharma downgraded to Neutral from Buy at BTIG

Joon LeeTruist Financial

Truist Financial

$100→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Truist Financial downgrades Verona Pharma (VRNA) to a Hold

Yasmeen RahimiPiper Sandler

Piper Sandler

$160→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Verona Pharma downgraded to Neutral from Overweight at Piper SandlerVerona Pharma downgraded to Neutral from Overweight at Piper Sandler

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Downgraded

07/10/25

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe ResearchVerona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Mohit BansalWells Fargo

Wells Fargo

$138→$107

Hold

2.12%

Upside

Downgraded

07/10/25

Verona Pharma (VRNA) was downgraded to a Hold Rating at Wells Fargo

Edward NashCanaccord Genuity

Canaccord Genuity

$106→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at CanaccordVerona Pharma downgraded to Hold from Buy at Canaccord

Andrew TsaiJefferies

Jefferies

$140→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Verona Pharma downgraded to Hold from Buy at JefferiesVerona Pharma downgraded to Hold from Buy at Jefferies

Tara BancroftTD Cowen

TD Cowen

$100→$107

Hold

2.12%

Upside

Downgraded

07/09/25

Merck's Acquisition of Verona Pharma Caps Stock's Upside Potential, Downgraded to Hold

Olivia BrayerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

-4.56%

Downside

Reiterated

06/11/25

Verona Pharma (VRNA) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verona Pharma

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+19.85%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +19.85% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+45.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +45.35% per trade.

1 Year

Olivia BrayerCantor Fitzgerald

Success Rate

2/2 ratings generated profit

Average Return

+45.35%

reiterated a buy rating last month

Copying Olivia Brayer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.35% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+45.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +45.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRNA Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRNA has received 12 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. VRNA average Analyst price target in the past 3 months is 106.22.

Each month's total comprises the sum of three months' worth of ratings.

VRNA Financial Forecast

VRNA Earnings Forecast

Next quarter’s earnings estimate for VRNA is $0.03 with a range of -$0.07 to $0.31. The previous quarter’s EPS was -$0.02. VRNA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year VRNA has Preformed in-line its overall industry.

VRNA Sales Forecast

Next quarter’s sales forecast for VRNA is $95.37M with a range of $83.00M to $120.00M. The previous quarter’s sales results were $76.55M. VRNA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year VRNA has Preformed in-line its overall industry.

VRNA Stock Forecast FAQ

What is VRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Verona Pharma Plc’s 12-month average price target is 106.22.

What is VRNA’s upside potential, based on the analysts’ average price target?

Verona Pharma Plc has 1.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRNA a Buy, Sell or Hold?

Verona Pharma Plc has a consensus rating of Hold which is based on 1 buy ratings, 10 hold ratings and 0 sell ratings.

What is Verona Pharma Plc’s price target?

The average price target for Verona Pharma Plc is 106.22. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $107.00 ,the lowest forecast is $100.00. The average price target represents 1.37% Increase from the current price of $104.78.

What do analysts say about Verona Pharma Plc?

Verona Pharma Plc’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of VRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Verona Pharma (VRNA) Stock Forecast & Price Target

VRNA Analyst Ratings

VRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Verona Pharma

VRNA Analyst Recommendation Trends

VRNA Financial Forecast

VRNA Earnings Forecast

VRNA Sales Forecast

VRNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts